{"protocolSection": {"identificationModule": {"nctId": "NCT00069823", "orgStudyIdInfo": {"id": "157"}, "secondaryIdInfos": [{"id": "U01HL072968", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U01HL072968"}], "organization": {"fullName": "Johns Hopkins Bloomberg School of Public Health", "class": "OTHER"}, "briefTitle": "Study of Acid Reflux in Asthma", "officialTitle": "The Study of Acid Reflux in Asthma"}, "statusModule": {"statusVerifiedDate": "2012-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-09"}, "primaryCompletionDateStruct": {"date": "2008-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2003-10-01", "studyFirstSubmitQcDate": "2003-10-02", "studyFirstPostDateStruct": {"date": "2003-10-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-14", "resultsFirstSubmitQcDate": "2012-09-18", "resultsFirstPostDateStruct": {"date": "2012-10-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-12-17", "lastUpdatePostDateStruct": {"date": "2012-12-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Robert Wise", "investigatorTitle": "Professor", "investigatorAffiliation": "Johns Hopkins Bloomberg School of Public Health"}, "leadSponsor": {"name": "Johns Hopkins Bloomberg School of Public Health", "class": "OTHER"}, "collaborators": [{"name": "American Lung Association Asthma Clinical Research Centers", "class": "OTHER"}, {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.", "detailedDescription": "BACKGROUND:\n\nGastroesophageal reflux (GERD) is frequent in asthmatics with poor asthma control, often occurs without symptoms, and can induce bronchoconstriction. Poorly controlled asthmatics are often treated for GERD with drugs that suppress gastric acid, but this treatment is expensive and the benefit of such treatment is not established. Proton pump inhibitors are a relatively new class of medications that provide highly effective treatment for GERD and associated problems. This success has led many doctors to begin PPI treatment in their asthma patients in an attempt to achieve better asthma control.\n\nDESIGN NARRATIVE:\n\nThe randomized, placebo-controlled trial will enroll 400 asthmatics, ages 18 or older, who have poor asthma control on inhaled steroids, defined on the basis of excessive bronchodilator use, nocturnal awakenings, or frequent exacerbations. Participants will be randomly assigned to treatment with either a proton pump inhibitor, esomeprazole (Nexium) 40 mg twice a day, or matching placebo. The presence, severity, and temporal relationship of GERD to asthma symptoms will be documented with 24 hour ambulatory esophageal potential Hydrogen (pH) probe monitoring, but participants will be enrolled irrespective of the severity of GERD. The primary outcome measure is the proportion of participants who have exacerbations of asthma within a 6-month period defined by asthma diaries and interviews. Secondary outcome measures include asthma symptom and control scores, asthma-specific and generic health-related quality of life, GERD symptoms, health care use, pulmonary function, and airways reactivity. Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma."}, "conditionsModule": {"conditions": ["Asthma", "Lung Diseases", "Lung Diseases, Obstructive"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 403, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Esomeprazole", "type": "EXPERIMENTAL", "description": "Proton pump inhibitor of gastric acid", "interventionNames": ["Drug: Esomeprazole"]}, {"label": "Placebo for esomeprazoe", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo proton pump inhibitor"]}], "interventions": [{"type": "DRUG", "name": "Esomeprazole", "description": "Proton pump inhibitor 40 mg orally twice daily", "armGroupLabels": ["Esomeprazole"], "otherNames": ["Nexium"]}, {"type": "DRUG", "name": "Placebo proton pump inhibitor", "description": "Placebo proton pump inhibitor", "armGroupLabels": ["Placebo for esomeprazoe"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion", "description": "Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow \\>=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma", "timeFrame": "Baseline to 24 Weeks"}], "secondaryOutcomes": [{"measure": "Exacerbation Components: >=30% Drop in Peak Expiratory Flow on 2 Consecutive Days", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Exacerbation Components: Urgent Care Visit", "timeFrame": "Measured at Month 6"}, {"measure": "Exacerbation Components: New Use of Oral Corticosteroids", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Use of Rescue Medications", "description": "Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Night Awakening", "description": "Rate of awakening at night because of asthma symptoms", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Pulmonary Function: Change in Prebronchodilator FEV1", "description": "Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity", "description": "Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Pulmonary Function: Change in Peak Flow Rate", "description": "Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Pulmonary Function: Change in PC20", "description": "Mean Change in the dose of methacholine that results in a 20% drop in FEV1", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Juniper Asthma Control Score(JACQ)", "description": "Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Asthma Symptom Utility Index (ASUI)", "description": "Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)", "description": "Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component", "description": "Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component", "description": "Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score", "description": "Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.", "timeFrame": "Baseline to 24 Weeks"}, {"measure": "Change in Number of Gastric Symptoms: No. of Symptoms", "description": "Mean change", "timeFrame": "Baseline to 24 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The general goal of patient selection is to enroll patients for whom asthma physicians might prescribe GERD treatment, but where there is uncertainty whether it might be effective.\n* Age 18 or older\n* Physician diagnosed asthma\n* If amount of air expired in the first second during a forced expiratory maneuver (FEV1) is greater than or equal to 70% predicted normal pre-bronchodilator: demonstrate methacholine 20% from post-diluent baseline (PC20). PC20 less than 16 mg/ml during Visit 1\n* If FEV1 less than 70% and greater than or equal to 50% predicted normal pre-bronchodilator: demonstrate 12% reversibility during Visit 1 or within past 12 months\n* Currently on stable dose of daily inhaled steroids for asthma control, i.e., inhaled corticosteroid equivalent to 400 ug/day of fluticasone44 or greater for 8 weeks or longer\n* Poor asthma control: Either of the following; a score of 1.5 or greater on the Juniper Asthma Control Questionnaire; two or more episodes of asthma symptoms in the past 12 months with each episode requiring at least one of the following: an emergency department visit, unscheduled physician visit, prednisone course, hospitalization\n* Non-smoker for 6 months or longer\n* Less than 10 pack/year smoking history\n\nExclusion Criteria:\n\n* Surgery: Previous anti-reflux or peptic ulcer surgery\n* Pulmonary function: FEV1 less than 50% predicted normal pre-bronchodilator\n* GERD Symptoms: Severe reflux constituting a clinical indication for treatment with a PPI or H2 blocker, typically two or more episodes per week of heartburn requiring antacids\n* Other major chronic illnesses; conditions which in the judgment of the Study Physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, congestive heart failure, stroke, severe hypertension, Type 1 insulin dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, major neuropsychiatric disorder\n* Medication use: Anti-reflux medication (proton pump inhibitors or H2 blockers) within 1 month Theophylline, azoles, iron, anti-coagulants, insulin (for Type I diabetes), digitalis, any investigative drugs within 1 month\n* Drug allergy: Previous adverse effects from proton pump inhibitors or methacholine challenge\n* Females of childbearing potential: Pregnant or lactating, unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal)\n* Inability or unwillingness to provide consent\n* Inability to perform baseline measurements\n* Completion of less than 10 of the last 14 days of screening period diary entry\n* Inability to be contacted by telephone\n* Intention to move out of the area within 6 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert Wise", "affiliation": "Johns Hopkins University School of Public Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Alabama at Birmingham", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "University of California, San Diego", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "National Jewish Medical and Research Center", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Nemours Childrens Clinic", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "University of Miami", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Northwestern Memorial Hospital", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Indiana University ACRC", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "LSUHSC Pulmonary Critical Care", "city": "New Orleans", "state": "Louisiana", "zip": "70112", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "University of Minnesota", "city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Univ of MO Kansas City School of Medicine", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Washington University School of Medicine", "city": "St. Louis", "state": "Missouri", "zip": "63310-1093", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "North Shore-LIJ Medical Center", "city": "New Hyde Park", "state": "New York", "zip": "11040", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "NYU School of Medicine", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "New York Medical College", "city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States", "geoPoint": {"lat": 41.07482, "lon": -73.77513}}, {"facility": "Duke University", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Thomas Jefferson Hospital Pulmonary Lab", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030-3411", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Northern New England Consortium", "city": "Colchester", "state": "Vermont", "zip": "05446", "country": "United States", "geoPoint": {"lat": 44.54394, "lon": -73.14791}}]}, "referencesModule": {"references": [{"pmid": "23026499", "type": "DERIVED", "citation": "Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA, Wise RA. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol. 2012 Nov;130(5):1078-84. doi: 10.1016/j.jaci.2012.07.058. Epub 2012 Sep 29."}, {"pmid": "22885561", "type": "DERIVED", "citation": "Bime C, Wei CY, Holbrook J, Smith LJ, Wise RA. Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. Prim Care Respir J. 2012 Dec;21(4):398-404. doi: 10.4104/pcrj.2012.00073."}, {"pmid": "19661245", "type": "DERIVED", "citation": "DiMango E, Holbrook JT, Simpson E, Reibman J, Richter J, Narula S, Prusakowski N, Mastronarde JG, Wise RA; American Lung Association Asthma Clinical Research Centers. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med. 2009 Nov 1;180(9):809-16. doi: 10.1164/rccm.200904-0625OC. Epub 2009 Aug 6."}, {"pmid": "19357404", "type": "DERIVED", "citation": "American Lung Association Asthma Clinical Research Centers; Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009 Apr 9;360(15):1487-99. doi: 10.1056/NEJMoa0806290."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The planned enrollment was for 400 participants, 403 participants actually were enrolled and randomized in the trial. It is not uncommon for clinical trials not to exactly meet the sample size stated in the protocol.", "groups": [{"id": "FG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "FG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "The design was for 200 participants per group, the study did not exactly meet the design.", "numSubjects": "199"}, {"groupId": "FG001", "comment": "The design was for 200 participants per group, the study did not exactly meet the design.", "numSubjects": "203"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "193"}, {"groupId": "FG001", "numSubjects": "200"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Did not have follow-up diary cards", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "BG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "199"}, {"groupId": "BG001", "value": "203"}, {"groupId": "BG002", "value": "402"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42", "spread": "13"}, {"groupId": "BG001", "value": "42", "spread": "13"}, {"groupId": "BG002", "value": "42", "spread": "13"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "273"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "129"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Race or ethnic group was self-reported.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "103"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "205"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "152"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "35"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Asthma medication use", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Inhaled corticosteroids", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "94"}]}]}, {"title": "Combination of fluticasone and salmeterol", "categories": [{"measurements": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "159"}, {"groupId": "BG002", "value": "308"}]}]}]}, {"title": "Body-mass index >=30", "description": "The body-mass index is the weight in kilograms divided by the square of the height in meters.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "BMI >=30", "categories": [{"measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "209"}]}]}, {"title": "BMI <30", "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "193"}]}]}]}, {"title": "Conditions other than asthma", "description": "These conditions were self-reported.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Gastroesophageal reflux disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "59"}]}]}, {"title": "No GER reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "161"}, {"groupId": "BG001", "value": "182"}, {"groupId": "BG002", "value": "343"}]}]}]}, {"title": "Former smoker", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Former Smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "71"}]}]}, {"title": "Never smoked", "categories": [{"measurements": [{"groupId": "BG000", "value": "159"}, {"groupId": "BG001", "value": "172"}, {"groupId": "BG002", "value": "331"}]}]}]}, {"title": "Health Care Visits", "description": "Unscheduled health care visit for asthma in previous year", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Health care visit for asthma exacerbation", "categories": [{"measurements": [{"groupId": "BG000", "value": "126"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "235"}]}]}, {"title": "No visit", "categories": [{"measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "167"}]}]}]}, {"title": "Pulmonary function", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Participants with 20% post-diluent measurement", "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "175"}]}]}, {"title": "20% from post-diluent contraindicated", "categories": [{"measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "219"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "potential Hydrogen (pH) monitoring", "description": "Results of ambulatory measure of esophageal potential Hydrogen (pH) for 16 to 24 hours. Test were considered positive if pH was less than 4 for more than 5.8% of the total tiem, 8.2% of upright time, or 3.5% of supine time.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Positive result", "categories": [{"measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "123"}]}]}, {"title": "Negative result", "categories": [{"measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "181"}]}]}, {"title": "Missing result", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "98"}]}]}]}, {"title": "%Predicted amount of air expired in the first second during a forced expiration pre broncho-dilator", "description": "Percent of the predicted value for the amount of air expired in the first second during a forced expiratory maneuver (FEV1) based on gender, age and ethnicity that the measured value is.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78", "spread": "15"}, {"groupId": "BG001", "value": "76", "spread": "16"}, {"groupId": "BG002", "value": "77", "spread": "16"}]}]}]}, {"title": "Age of onset of asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17", "spread": "17"}, {"groupId": "BG001", "value": "17", "spread": "16"}, {"groupId": "BG002", "value": "17", "spread": "16"}]}]}]}, {"title": "Age of participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "at randomization", "categories": [{"measurements": [{"groupId": "BG000", "value": "42", "spread": "13"}, {"groupId": "BG001", "value": "42", "spread": "13"}, {"groupId": "BG002", "value": "42", "spread": "13"}]}]}, {"title": "at onset of asthma", "categories": [{"measurements": [{"groupId": "BG000", "value": "17", "spread": "17"}, {"groupId": "BG001", "value": "17", "spread": "16"}, {"groupId": "BG002", "value": "17", "spread": "16"}]}]}]}, {"title": "Asthma scores", "description": "Asthma Control Score (ACS)ranges from 0 to 6, lower scores indicating better asthma control and 0.5 as the minimal clinically important difference; Asthma Symptom Utility Index (ASUI) score ranges from 0 to 1, higher scores indicating less severe asthma; Mini-Asthma Quality of Life Questionnaire (mini-AQLQ) score range from 1 to 7, higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score", "classes": [{"title": "ACQ", "categories": [{"measurements": [{"groupId": "BG000", "value": "1.9", "spread": "0.8"}, {"groupId": "BG001", "value": "1.8", "spread": "0.8"}, {"groupId": "BG002", "value": "1.8", "spread": "0.8"}]}]}, {"title": "ASUI", "categories": [{"measurements": [{"groupId": "BG000", "value": "0.74", "spread": "0.18"}, {"groupId": "BG001", "value": "0.76", "spread": "0.15"}, {"groupId": "BG002", "value": "0.75", "spread": "0.15"}]}]}, {"title": "mini asthma quality of life questionnaire", "categories": [{"measurements": [{"groupId": "BG000", "value": "4.7", "spread": "1.2"}, {"groupId": "BG001", "value": "4.7", "spread": "1.2"}, {"groupId": "BG002", "value": "4.7", "spread": "1.2"}]}]}]}, {"title": "Percent change in FEV1 after bronchodilator", "description": "The percent difference in FEV1 before and after using a bronchodilator (albuterol) divided by the value before bronchodilation.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent change", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10", "spread": "10"}, {"groupId": "BG001", "value": "11", "spread": "16"}, {"groupId": "BG002", "value": "11", "spread": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Exacerbation Components: >=30% Drop in Peak Expiratory Flow on 2 Consecutive Days", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person-year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.7"}, {"groupId": "OG001", "value": "2.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.35", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8", "ciUpperLimit": "2.0"}]}, {"type": "SECONDARY", "title": "Exacerbation Components: Urgent Care Visit", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person-year", "timeFrame": "Measured at Month 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.79", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6", "ciUpperLimit": "1.5"}]}, {"type": "PRIMARY", "title": "Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion", "description": "Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow \\>=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.3"}, {"groupId": "OG001", "value": "2.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The rates of EPACs were compared using incidence-rate ratios (IRR). IRR and P value were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.66", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8", "ciUpperLimit": "1.5"}]}, {"type": "SECONDARY", "title": "Exacerbation Components: New Use of Oral Corticosteroids", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.62", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6", "ciUpperLimit": "1.3"}]}, {"type": "SECONDARY", "title": "Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person-year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.4"}, {"groupId": "OG001", "value": "4.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.87", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8", "ciUpperLimit": "1.3"}]}, {"type": "SECONDARY", "title": "Use of Rescue Medications", "description": "Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person-year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.0"}, {"groupId": "OG001", "value": "2.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Incidence-rate ratios and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.62", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "0.9", "ciPctValue": "95", "ciLowerLimit": "0.7", "ciUpperLimit": "1.3"}]}, {"type": "SECONDARY", "title": "Night Awakening", "description": "Rate of awakening at night because of asthma symptoms", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events per person-year", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Incidence-rate ratios and P values were estimated with the use of negative binomial regression models with robust variance estimates.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.70", "pValueComment": "P values are for the treatment effect of esomeprazole as compared with placebo.", "statisticalMethod": "Negative binomial regression", "paramType": "Incidence-Rate Ratio", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6", "ciUpperLimit": "1.4"}]}, {"type": "SECONDARY", "title": "Pulmonary Function: Change in Prebronchodilator FEV1", "description": "Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.", "populationDescription": "The analyses are based on data from 191 participants in the placebo group and 201 in the esomeprazole group, with the following exception: 41 participants in the placebo group and 37 in the esomeprazole group for measurement of 20% post-diluent baseline (PC20).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "lowerLimit": "-0.06", "upperLimit": "0.01"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-0.04", "upperLimit": "0.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The treatment effect is the mean change in the Esomeprazole group - mean change in placebo group", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.36", "pValueComment": "P values were calculated with the use of linear regression.", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group, e.g. 0.00 - (-0.02) = -0.03 (rounding)"}]}, {"type": "SECONDARY", "title": "Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity", "description": "Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "lowerLimit": "-0.06", "upperLimit": "0.01"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-0.04", "upperLimit": "0.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.30", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Final Values)", "paramValue": "0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Pulmonary Function: Change in Peak Flow Rate", "description": "Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters/min", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "lowerLimit": "-3.5", "upperLimit": "9.9"}, {"groupId": "OG001", "value": "9.2", "lowerLimit": "1.8", "upperLimit": "16.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.24", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Final Values)", "paramValue": "6.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.0", "ciUpperLimit": "16.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.1", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Pulmonary Function: Change in PC20", "description": "Mean Change in the dose of methacholine that results in a 20% drop in FEV1", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/ml", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "lowerLimit": "0.2", "upperLimit": "2.9"}, {"groupId": "OG001", "value": "0.3", "lowerLimit": "-1.4", "upperLimit": "0.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.04", "statisticalMethod": "Regression, Linear", "paramType": "Treatment Effect", "paramValue": "-1.8", "ciPctValue": "95", "ciLowerLimit": "-3.6", "ciUpperLimit": "-0.1"}]}, {"type": "SECONDARY", "title": "Change in Juniper Asthma Control Score(JACQ)", "description": "Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "lowerLimit": "-0.4", "upperLimit": "-0.2"}, {"groupId": "OG001", "value": "-0.2", "lowerLimit": "-0.3", "upperLimit": "-0.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.11", "statisticalMethod": "Regression, Linear", "paramType": "Treatment Effect", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0", "ciUpperLimit": "0.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in Asthma Symptom Utility Index (ASUI)", "description": "Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "lowerLimit": "0.03", "upperLimit": "0.07"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "0.01", "upperLimit": "0.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.11", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "-0.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.01", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)", "description": "Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "lowerLimit": "0.2", "upperLimit": "0.4"}, {"groupId": "OG001", "value": "0.3", "lowerLimit": "0.2", "upperLimit": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.33", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2", "ciUpperLimit": "0.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component", "description": "Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "lowerLimit": "1.1", "upperLimit": "2.9"}, {"groupId": "OG001", "value": "1.1", "lowerLimit": "0.3", "upperLimit": "1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.16", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.0", "ciUpperLimit": "0.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.6", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component", "description": "Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.8", "upperLimit": "1.1"}, {"groupId": "OG001", "value": "0.4", "lowerLimit": "-0.5", "upperLimit": "1.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.56", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "2.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.78", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score", "description": "Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "lowerLimit": "-0.21", "upperLimit": "-0.12"}, {"groupId": "OG001", "value": "-0.16", "lowerLimit": "-0.20", "upperLimit": "-0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.76", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}, {"type": "SECONDARY", "title": "Change in Number of Gastric Symptoms: No. of Symptoms", "description": "Mean change", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "symptoms", "timeFrame": "Baseline to 24 Weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "40 mg of placebo twice daily"}, {"id": "OG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "lowerLimit": "-2.1", "upperLimit": "-1.3"}, {"groupId": "OG001", "value": "-1.9", "lowerLimit": "-2.3", "upperLimit": "-1.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.39", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.8", "ciUpperLimit": "0.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3", "estimateComment": "Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "40 mg of placebo twice daily", "seriousNumAffected": 16, "seriousNumAtRisk": 199, "otherNumAffected": 0, "otherNumAtRisk": 199}, {"id": "EG001", "title": "Esomeprazole", "description": "40 mg of esomeprazole twice daily", "seriousNumAffected": 10, "seriousNumAtRisk": 203, "otherNumAffected": 0, "otherNumAtRisk": 203}], "seriousEvents": [{"term": "Asthma exacerbation requiring hospitalization", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 193}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 203}]}, {"term": "Hospitalization or emergency department visit for surgery, trauma, or other acute illness", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 193}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 203}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Death from complications after surgery for endobronchial tumor", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Hospitalization for possible cardiac ischemia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 193}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 130}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Ellen Brown", "organization": "Johns Hopkins University", "email": "ala-acrc@jhsph.edu", "phone": "443-287-3170"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Lung Disease", "relevance": "HIGH"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "asFound": "Lung Diseases, Obstructive", "relevance": "HIGH"}, {"id": "M8880", "name": "Gastroesophageal Reflux", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000064098", "term": "Esomeprazole"}, {"id": "D000054328", "term": "Proton Pump Inhibitors"}], "ancestors": [{"id": "D000000897", "term": "Anti-Ulcer Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M30204", "name": "Esomeprazole", "asFound": "Core", "relevance": "HIGH"}, {"id": "M27630", "name": "Proton Pump Inhibitors", "asFound": "Best Practice", "relevance": "HIGH"}, {"id": "M4188", "name": "Antacids", "relevance": "LOW"}, {"id": "M4219", "name": "Anti-Ulcer Agents", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}